Vasiliki Pantazou1, Caroline Pot2, Renaud Du Pasquier2, Géraldine Le Goff3, Marie Théaudin4. 1. Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland; Laboratory of Neuroimmunology, Neuroscience Research Center of the Lausanne University Hospital, Epalinges, Switzerland; Laboratory of Myelination, INSERM, CNRS, Institut du Cerveau, Paris, France. Electronic address: vasiliki.pantazou@chuv.ch. 2. Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland; Laboratory of Neuroimmunology, Neuroscience Research Center of the Lausanne University Hospital, Epalinges, Switzerland. 3. Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland. 4. Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: marie.theaudin@chuv.ch.
Abstract
BACKGROUND: Discontinuing fingolimod (FTY) in older patients is a growing concern with little evidence supporting the decision to pursue treatment and reasonable doubt for disease reactivation after withdrawal. OBJECTIVE: To estimate the incidence of recurrence of disease activity (RDA) and rebound after FTY withdrawal in patients older than 50 years. METHODS: Retrospective analysis of all MS patients in our clinic who discontinued FTY after at least 6 months of treatment, according to disease activity on FTY and age at discontinuation. RDA was defined as the occurrence of either clinical and/or MRI activity in the 6 months after FTY withdrawal and rebound when the levels of disease activity surpassed pretreatment activity. RESULTS: From the 128 patients who discontinued FTY since 2011, up to 35.2% of patients experienced evidence of disease activity and 12.5% had a rebound. The incidence of both RDA and rebound was not different among individuals who had persistent disease activity on FTY to those who stopped FTY for other reasons than inefficacy (RDA: 25.5% vs 20.5%, p = 0.353 rebound: 14.5% vs 11%, p = 0.596). Negative predictive factors for RDA were younger age at disease onset (p = 0.036), highly active disease at baseline (p = 0.003) and previous treatment with NTZ (p = 0.013). Older age at FTY discontinuation did not reduce the risk of RDA in patients previously stable on treatment (OR 0.972, 95% CI 0.871-1.085, p = 0.613), although the incidence of RDA/rebound was half less in the older patients (36.5% in the <50 vs 19% in the ≥50 year-old, p = 0.174) and none of the patients over 60 experienced RDA. CONCLUSION: Although there is a tendency for a lower risk of disease reactivation in the older patients, the incidence of RDA, and even rebound, is not negligible between the age of 50 and 60 years, even in patients with previously stable MS on FTY.
BACKGROUND: Discontinuing fingolimod (FTY) in older patients is a growing concern with little evidence supporting the decision to pursue treatment and reasonable doubt for disease reactivation after withdrawal. OBJECTIVE: To estimate the incidence of recurrence of disease activity (RDA) and rebound after FTY withdrawal in patients older than 50 years. METHODS: Retrospective analysis of all MS patients in our clinic who discontinued FTY after at least 6 months of treatment, according to disease activity on FTY and age at discontinuation. RDA was defined as the occurrence of either clinical and/or MRI activity in the 6 months after FTY withdrawal and rebound when the levels of disease activity surpassed pretreatment activity. RESULTS: From the 128 patients who discontinued FTY since 2011, up to 35.2% of patients experienced evidence of disease activity and 12.5% had a rebound. The incidence of both RDA and rebound was not different among individuals who had persistent disease activity on FTY to those who stopped FTY for other reasons than inefficacy (RDA: 25.5% vs 20.5%, p = 0.353 rebound: 14.5% vs 11%, p = 0.596). Negative predictive factors for RDA were younger age at disease onset (p = 0.036), highly active disease at baseline (p = 0.003) and previous treatment with NTZ (p = 0.013). Older age at FTY discontinuation did not reduce the risk of RDA in patients previously stable on treatment (OR 0.972, 95% CI 0.871-1.085, p = 0.613), although the incidence of RDA/rebound was half less in the older patients (36.5% in the <50 vs 19% in the ≥50 year-old, p = 0.174) and none of the patients over 60 experienced RDA. CONCLUSION: Although there is a tendency for a lower risk of disease reactivation in the older patients, the incidence of RDA, and even rebound, is not negligible between the age of 50 and 60 years, even in patients with previously stable MS on FTY.
Authors: William M Rowles; Wan-Yu Hsu; Kira McPolin; Alyssa Li; Steven Merrill; Chu-Yueh Guo; Ari J Green; Jeffrey Marc Gelfand; Riley M Bove Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-05-17